# Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis

> **NCT06503237** · NA · RECRUITING · sponsor: **The First Affiliated Hospital of University of Science and Technology of China** · enrollment: 18 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Anti-CD19 CART cells will be given IV at split doses.

## Key facts

- **NCT ID:** NCT06503237
- **Lead sponsor:** The First Affiliated Hospital of University of Science and Technology of China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06503237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06503237, "Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06503237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*